spdb dm4

SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, employing the maytansine-based payload DM4 (a tubulin inhibitor) connected through a SPDB linker. This compound demonstrates significant anti-tumor efficacy.

Sulfo-SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs) that employs the maytansine-based payload (DM4, an antitubulin agent) connected through the sulfo-SPDB linker.

Lys-Nε-SPDB-DM4 is a drug-linker conjugate that integrates the tubulin inhibitor DM4 with the linker Lys-Nε-SPDB, enabling the formation of an antibody-drug conjugate (ADC).

Tusamitamab ravtansine (SAR-408701) is a DM4-linked anti-CEACAM5 antibody-drug conjugate (ADC) comprising a humanized monoclonal antibody targeting carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5) conjugated to a cytotoxic maytansinoid, selectively engaging CEACAM5-positive tumor cells [1].

Anti-CCL2 (Carlumab)-SPDB-DM4 is an antibody-drug conjugate (ADC) composed of the human-derived anti-CCL2 (chemokine ligand 2) antibody Carlumab, linked to the microtubule inhibitor DM4 via the SPDB linker. The toxic component and linker of the ADC are sulfo-SPDB-DM4. This compound is utilized in cancer research.

Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4 is an antibody-drug conjugate (ADC) composed of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody, Lifastuzumab, linked via SPDB to the tubulin inhibitor DM4. The toxic component and linker of this ADC is sulfo-SPDB-DM4. This compound can be utilized for cancer research.

SPDB-DM4 is a part of the ADC. It is composed of DM1 (a microtubule inhibitor, also an antibody-encodable aristolochic acid alkaloid, used to overcome the systemic toxicity associated with aristolochic acid and enhance tumor-specific delivery) and SPDB, and exhibits highly efficient anti-tumor activity.

SPDB is a degradable ADC linker that can be used to synthesize antibody-drug conjugates. SPDB is a small fragment attached to the DM4 conjugate and conjugated to the antibody using a disulfide bond.

ADC Control Human IgG1-DM4 serves as the isotype control for ADC Human IgG1-DM4. It comprises an antibody portion identified as HumanIgG1kappa, Isotype Control, whereas the toxic molecule and linker components are SPDB-DM4.